

## Potential and challenges with antibody fragments

抗体片段的机遇和挑战
Potential 机遇
Challe

Challenges挑战

- Improved kinetics in solid tumors 实体瘤中提高药物动力学
- Enables binding of targets not accessible to Ab 可结合靶点而不影响抗体
- Higher diversity in specific binding structures 特殊结合位点上具有更高的可变性
- Advantages in manufacturing yeast and bacterial systems can be used

工业生产上的优势——可使用大肠杆菌和酵母 系统

- Lower stability and solubility 可溶性和稳定性差
- Sometimes low target retention 某些片段靶向性差
- Varying expression levels 表达水平不同
- Lack of generic purification protocols

缺少通用的纯化方案





## **Properties of Protein L** 蛋白L的属性 Light chain Lambda or <u>Kappa</u> Protein L binds:结合 - to the variable region of most Capto™ L subtypes of Ab kappa light chain 结合抗体kappa轻链可变区 – a wider range of Ab classes than Protein A or G 比蛋白A或蛋白G有更广的抗体种类 - Ab fragments抗体片段; Fabs, Dabs and scFv – without interfering with antigen binding 对于抗原的结合没有干扰 # imagination at work





## Purification of human Fab 纯化人源Fab


Sample: Fab kappa derived from  $IgG_1$  in E. coli cell culture supernatant

样品:源于大肠杆菌细胞培养表达的IgG1的kappa片段

• Concentration in feed: 1 mg/ml 上样浓度: 1 mg/ml

pl: 8.5 等电点: 8.5

● Mw: 48 kDa 分子量: 48kDa





# Capto™ L: Design of Experiments (DoE) Capto™ L实验设计(DoE)★

### DoE:

• Wash pH: 4.5-7.5

• Wash [NaCl]: 40-460 mM

• Elution pH: 2.9-3.1

# Constants: 非变量 CCC design


Load 15 mg/ml (70% of DBC), residence time 4 minutes, wash volume 7 CV 15mg/ml上样(动态载量的70%),保留时间4min,冲洗7倍柱体积


Responses: 响应值

Yield and E. coli protein (ECP) content


收率及大肠杆菌蛋白含量



















# Outline概况 Introduction介绍 Applications应用 • Fab • Dab • scFv Summary 总结











## Challenging customer application

客户应用的挑战

BIBITEC GmbH is a German CMO, specialized in the production of recombinant proteins and MAbs for use in clinical trials up to phase III using mammalian cells.

BIBITEC GmbH是一家德国的CMO公司,专业生产用哺乳动物细胞培养、用于三期临床试验的重组蛋白和单克隆抗体。

In this application, the challenge was to **purify scFv fusion protein (57 kDa) from transgenic animal plasma**.

从转基因动物中纯化scFv融合蛋白(57kDab)的应用挑战

The sample had high content of albumin, IgG as well as many other plasma proteins

.样品中含有大量的白蛋白、IgG及其它血浆蛋白

Dynamic binding capacity ( $\mathring{Q}_{b, 10\%}$ ): 23 mg/ml


动态结合载量: 23 mg/ml









scFv, ~28 kDa Bis-scFv, bispecific, ~55 kDa











## Scale-up study放大研究

| Contaminant levels    | Plasma                | Run 1                 | Run 2                 | Reduction |
|-----------------------|-----------------------|-----------------------|-----------------------|-----------|
| Albumin (ppm)         | $3.7 \times 10^7$     | 2.8 x 10 <sup>4</sup> | 2.8 x 10 <sup>4</sup> | 3 log     |
| IgG (ppm)             | 1.8 x 10 <sup>8</sup> | $7.6 \times 10^3$     | $7.9 \times 10^3$     | 4.5 log   |
| Plasma proteins (ppm) | 1.3 x 10 <sup>9</sup> | 1.6 x 10 <sup>4</sup> | 1.8 x 10 <sup>4</sup> | 5 log     |
| Pr L leakage (ppm)    |                       | ≤2                    | ≤2                    |           |

The yield was at least 89% for both runs 两次实验的收率至少达到89%



## Conclusions: scFv application example 结论: scFv应用实例

- Dynamic binding capacity: 23 mg/ml 动态结合载量: 23mg/ml
- Challenging sample 具有挑战性的样品
- Effective wash step developed 开发有效的清洗步骤
- High yields obtained: >89% 高回收率: >89%



Bis-scFv, bispecific, ~55 kDa



scFv, ~28 kDa





## Outline概况

Introduction介绍

Applications应用

- Fab
- Dab
- scFv

Summary 总结



## Summary总结

• Capto™ L is suitable for purification of antibody fragments containing kappa light chain;

Capto™ L适于含有kappa轻链的抗体片段的纯化

- Fab
- Dab
- ScFv
- Capto L purification show high yields and purity Capto™ L纯化表现出较高的收率和纯度









ÄKTA, HiTrap, HiScreen, MabSelect, Capto and Sepharose are trademarks of GE Healthcare companies. GE and GE Monogram are trademarks of General Electric Company.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.

© 2012 General Electric Company – All rights reserved.

GE Healthcare Bio-Sciences AB, a General Electric Company.

www.gelifesciences.com

GE Healthcare Bio-Sciences AB

Björkgatan 30

SE-731 84 Uppsala

Sweden

GE imagination at work

